ABBOTT LABORATORIES AND NAPRO BIOTHERAPEUTICS FILE PACLITAXEL ANDA
Advertisement
Abbott Laboratories (NYSE: ABT) and NaPro BioTherapeutics, Inc. (Nasdaq: NPRO) announced today that they have filed an Abbreviated New Drug Application (ANDA) with the U.S. food and Drug Administration (FDA) for paclitaxel, the most widely used anticancer compound in the United States.
"Abbott is building a superior portfolio of oncology products," said Christopher B. Begley, senior vice president, hospital products, Abbott Laboratories. "Submitting the paclitaxel ANDA is a major milestone in Abbott's plan to expand our presence in the oncology market."
"We are very hopeful that soon oncologists and cancer patients in the United States will have another high quality paclitaxel option," commented Leonard P. Shaykin, chairman and chief executive officer, NaPro BioTherapeutics.
Most read news
Other news from the department research and development
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
SciQuest Successfully Completes Implementation of Enterprise Reagent Manager to Maximize Research Operations for Eisai Research - Research asset management solution designed to improve Eisai Research Institute's supply chain efficiency
Great Lakes Announces Antimony Oxide Price Increases
Researchers discover particle which could 'cool the planet'
ExxonMobil Celebrates China's Fujian Facility Completion
Direvo and Danisco Collaboration Yields New Industrial Enzyme
Medical use for waste television screens
Chevron Phillips Chemical Names New General Counsel
Crompton Sells Colors Business to Sensient
3-D printing for building densely populated electronic assemblies investigated